Summary

Eligibility
for people ages 17 years and up (full criteria)
Location
at UC Davis
Dates
study started
study ends around

Description

Summary

CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).

Official Title

The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Refractory B Cell-mediated Autoimmune Diseases

Keywords

Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, CAR iNK, CAR NK, Cellular therapy, SLE, Induced pluripotent stem cell (iPSC), Anti-CD19 therapy, CNTY-101, Autoimmune disease, Lupus, IIM, DcSSc, Myositis, Polymyositis, Dermatomyositis, Anti-synthetase syndrome, Systemic sclerosis, Sclerosis, Muscular Diseases, Nephritis, Systemic Scleroderma, Diffuse Scleroderma, Autoimmune Diseases, Lymphodepleting Chemotherapy

Eligibility

Locations

  • UC Davis accepting new patients
    Sacramento California 957817 United States
  • Keck School of Medicine of University of Southern California accepting new patients
    Los Angeles California 90033 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Century Therapeutics, Inc.
ID
NCT06255028
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 48 study participants
Last Updated